Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 16/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22342185 | 0.92 | KEAP1 (0.64) | KEAP1ITGB3ITGA2BTSLP | |
| SCHEMBL22342263 | 0.87 | KEAP1 (0.63) | KEAP1ITGB3ITGA2BTSLP | |
| SCHEMBL22342385 | 0.84 | KEAP1 (0.60) | KEAP1TSLP | |
| SCHEMBL22342240 | 0.83 | KEAP1 (0.63) | KEAP1TSLPPLAU | |
| SCHEMBL22342178 | 0.82 | KEAP1 (0.61) | KEAP1TSLPPLAU | |
| SCHEMBL22341359 | 0.81 | KEAP1 (0.61) | KEAP1ITGB3 | |
| SCHEMBL22342209 | 0.81 | KEAP1 (0.59) | KEAP1ITGB3ITGA2BTSLPPLAU | |
| SCHEMBL22341326 | 0.80 | KEAP1 (0.60) | KEAP1TSLPPLAU | |
| SCHEMBL22342189 | 0.80 | KEAP1 (0.60) | KEAP1TSLPPLAU | |
| SCHEMBL22341357 | 0.78 | KEAP1 (0.58) | KEAP1TSLP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | ALMIRALL SA (ES) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | KEAP1, NFE2L2, HMOX1 | KEAP1 1/4885ITGB3 4873/4885ITGA2B 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.